A comparison of rocuronium potentiation responses to remimazolam, sevoflurane and propofol in eldery : A prospective comparative study.

JRCT ID: jRCT1031240017

Registered date:08/04/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Patients undergoing general anesthesia
• Date of first enrollment: 08/04/2024
• Target sample size: 48
• Study type: Interventional
• Intervention(s): The sedative of choice is remimazolam, sevoflurane, or propofol, depending on the envelope method. Blood samples are drawn during general anesthesia.

Outcome(s)

• Primary Outcome: PTC appearance time in remimazolam, sevoflurane, and propofol groups
• Secondary Outcome: T1 and T2 appearance time in sevoflurane, propofol, and remimazolam groups, and time to 100% TOF ratio after sugammadex administration. PTC, and rocuronium-rocuronium protein binding rate in blood at T1 and T2 appearance

Key inclusion & exclusion criteria

• Age minimum: >= 65age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1) Patients over 65 years
2) Patients with American Society of Anesthesiologists physical status classification 1-3.
3) Patients who receive written informed consent.

Exclude criteria

1. Patients with a history of allergy to muscle relaxants or antagonists
2. Patients with severe complications
3. patients with neuromuscular disease
4. Patients taking medications that may affect the effect of muscle relaxation.
5. Patients who are deemed inappropriate as research subjects by the principal investigator
6. Patients who refuse to participate in the study.

Related Information

• Primary Sponsor: Takagi Shunichi